Log in to your Inderes Free account to see all free content on this page.

Asarina Pharma

1 following

ShowingAll content types

Regulatory press release9/16/2024, 6:00 PM

Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024

Regulatory press release9/13/2024, 9:00 AM

Asarina Pharma applies for the delisting of the company's shares

Regulatory press release8/21/2024, 9:30 AM

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release7/22/2024, 6:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)

Regulatory press release7/18/2024, 3:45 PM

ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE

Regulatory press release6/27/2024, 9:33 AM

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Regulatory press release6/4/2024, 8:54 PM

ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023

Regulatory press release5/28/2024, 8:00 PM

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Regulatory press release5/21/2024, 9:50 AM

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Regulatory press release2/27/2024, 7:30 AM

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023

Regulatory press release11/30/2023, 9:30 AM

Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB

Regulatory press release11/16/2023, 7:33 AM

Asarina Pharma updates on partnering and financials

Regulatory press release8/23/2023, 6:30 AM

Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)

Regulatory press release5/23/2023, 7:02 AM

Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders

Regulatory press release5/22/2023, 9:15 AM

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Regulatory press release5/5/2023, 11:33 AM

Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

Regulatory press release4/28/2023, 6:30 PM

Asarina Pharma AB (publ) releases Annual Report 2022

Regulatory press release4/18/2023, 8:39 AM

Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

Regulatory press release4/1/2023, 12:20 PM

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

Regulatory press release2/27/2023, 7:30 AM

Asarina Pharma AB (publ) releases Year-End Report 2022

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.